SAGE

Sage Therapeutics Stock Price

59.88
-2.57 (-4.12%)
Upgrade to Real-Time
Afterhours (Closed)
59.88
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Sage Therapeutics Inc SAGE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-2.57 -4.12% 59.88 20:00:00
Close Price Low Price High Price Open Price Previous Close
59.88 59.30 61.42 61.27 62.45
Bid Price Ask Price Spread News
59.60 65.00 5.40 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
8,410 639,100 $ 60.02 $ 38,359,410 725,020 25.01 - 166.01
Last Trade Time Type Quantity Stock Price Currency
18:59:18 5 $ 59.61 USD

Sage Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 3.11B 51.97M 37.62M $ 6.87M $ - -13.38 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 1.80%

more financials information »

Sage Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SAGE Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week56.6662.6354.756359.491,067,1723.225.68%
1 Month51.7562.6346.2454.97797,1578.1315.71%
3 Months41.9462.6340.6650.04675,00117.9442.78%
6 Months26.7762.6325.2539.54938,98033.11123.68%
1 Year165.71166.0125.0157.46952,359-105.83-63.86%
3 Years64.49195.9725.01101.96675,217-4.61-7.15%
5 Years59.87195.9725.0184.28615,3780.010.02%

Sage Therapeutics Description

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.


Your Recent History
NASDAQ
SAGE
Sage Thera..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.